On January 18, 2022, the Pan-Canadian Formulary Advisory Panel will be presenting an information session with their recommendations for the development of a framework for a potential pan-Canadian prescription drug list, or formulary.
The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health (CADTH) at the request of Health Canada. The information session will focus on the principles for developing a pan-Canadian formulary framework, a sample list of prescribed drugs to include on the potential formulary as a test case, and criteria and processes for expanding the sample list. Registration is free.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Ontario proposes legislation to regulate preferred provider networks
Following two public consultations with stakeholders, the Government of Ontario (Ministry of Finance) is moving forward with legislation to regulate preferred provider networks (PPNs).Read More -
Canada’s Drug Agency releases new resource and data on drug approval and reimbursement pathway
Canada’s Drug Agency (CDA-AMC) published data on Canada’s drug system as part of the Data Systems and Analytics program.Read More -
PMPRB update: Guidelines for PMPRB Staff come into effect January 1, 2026; 2024 Annual Report
On January 1, 2026, the Guidelines for PMPRB Staff will come into effect. In November, the Patented Medicine Prices Review Board (PMPRB) held information sessions on the Guidelines to share technical ...Read More
